IDYA
IDEAYA Biosciences Inc
$
31.360
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
32.020
Open
31.760
VWAP
31.28
Vol
1.03M
Mkt Cap
2.75B
Low
30.565
Amount
32.25M
EV/EBITDA(TTM)
--
Total Shares
75.69M
EV
2.12B
EV/OCF(TTM)
--
P/S(TTM)
--
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
--
--
-0.550
-8.34%
--
--
-0.869
-41.67%
--
--
-0.873
+6.5%
Estimates Revision
The market is revising Upward the revenue expectations for IDEAYA Biosciences, Inc. (IDYA) for FY2025, with the revenue forecasts being adjusted by 347.76% over the past three months. During the same period, the stock price has changed by 25.44%.
Revenue Estimates for FY2025
Revise Upward
+347.76%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-3.35%
In Past 3 Month
Stock Price
Go Up
+25.44%
In Past 3 Month
17 Analyst Rating
54.34% Upside
Wall Street analysts forecast IDYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDYA is 48.40 USD with a low forecast of 30.00 USD and a high forecast of 79.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Buy
2 Hold
0 Sell
Strong Buy
54.34% Upside
Current: 31.360
Low
30.00
Averages
48.40
High
79.00
54.34% Upside
Current: 31.360
Low
30.00
Averages
48.40
High
79.00
JPMorgan
Overweight
maintain
$74 -> $79
2025-10-23
Reason
JPMorgan
Price Target
$74 -> $79
2025-10-23
maintain
Overweight
Reason
JPMorgan raised the firm's price target on Ideaya Biosciences to $79 from $74 and keeps an Overweight rating on the shares. The firm cites an increased probability of success for darovasertib in the neoadjuvant setting, to 70% from 60%, for the target bump. It estimates peak sales of darovasertib to be $500M in the U.S. alone. JPMorgan sees share upside for Ideaya into the metastatic uveal melanoma update.
RBC Capital
Outperform
maintain
$38 -> $41
2025-10-21
Reason
RBC Capital
Price Target
$38 -> $41
2025-10-21
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Ideaya Biosciences to $41 from $38 and keeps an Outperform rating on the shares. Ideaya Biosciences presented data on eye and visual acuity preservation from daro in the neo-adjuvant setting, suggesting evidence of very impressive anti-tumor efficacy leading to meaningful survival benefits, eye preservation and visual benefits, increasing the likelihood that upcoming phase III trials will read out positively, the analyst tells investors in a research note.
Goldman Sachs
Neutral
maintain
$27 -> $30
2025-10-21
Reason
Goldman Sachs
Price Target
$27 -> $30
2025-10-21
maintain
Neutral
Reason
Goldman Sachs raised the firm's price target on Ideaya Biosciences to $30 from $27 and keeps a Neutral rating on the shares. New data for Ideaya's darovasertib in first-line metastatic uveal melanoma showed median overall survival of 21.1 months, exceeding base expectations of 18-21 months and likely driving stock outperformance, the analyst tells investors in a resarch note. The results support optimism for the ongoing Phase 2/3 trial ahead of 2026 progression free survival data, though uncertainty remains regarding outcomes in the HLA-A2 negative subgroup, Goldman says.
JPMorgan
Anupam Rama
Overweight
maintain
$74
2025-09-25
Reason
JPMorgan
Anupam Rama
Price Target
$74
2025-09-25
maintain
Overweight
Reason
JPMorgan analyst Anupam Rama added a "Positive Catalyst Watch" on shares of Ideaya Biosciences into the updates for darovasertib. The firm keeps an Overweight rating on the shares with a $74 price target. After hosting a call with management, JPMorgan sees "plenty of value creating events" in the near-term for Ideaya. Darovasertib updates should continue to underscore the drug's "compelling emerging profile," the analyst tells investors in a research note. JPMorgan continues to see Ideaya shares as undervalued on darovasertib alone.
Guggenheim
NULL -> Buy
initiated
$50
2025-09-17
Reason
Guggenheim
Price Target
$50
2025-09-17
initiated
NULL -> Buy
Reason
Guggenheim initiated coverage of Ideaya Biosciences with a Buy rating and $50 price target.
Guggenheim
Paul Jeng
initiated
$50
2025-09-17
Reason
Guggenheim
Paul Jeng
Price Target
$50
2025-09-17
initiated
Reason
Guggenheim analyst Paul Jeng initiated coverage of Ideaya Biosciences with a Buy rating and $50 price target. Ideaya is a clinical-stage Biotech company with a deep precision oncology pipeline built through its in-house R&D engine and BD proficiencies, and the firm's investment thesis on the stock is anchored on the company's late-stage asset, darovasertib, which has the potential to become the leading treatment regimen for metastatic uveal melanoma across all lines of therapy, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for IDEAYA Biosciences Inc (IDYA.O) is -10.03, compared to its 5-year average forward P/E of -11.89. For a more detailed relative valuation and DCF analysis to assess IDEAYA Biosciences Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-11.89
Current PE
-10.03
Overvalued PE
-6.87
Undervalued PE
-16.91
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-8.30
Current EV/EBITDA
-5.36
Overvalued EV/EBITDA
5.27
Undervalued EV/EBITDA
-21.88
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
85.07
Current PS
31.86
Overvalued PS
180.63
Undervalued PS
-10.49
Financials
Annual
Quarterly
FY2025Q2
N/A
Total Revenue
FY2025Q2
YoY :
+36.78%
-88.81M
Operating Profit
FY2025Q2
YoY :
+46.84%
-77.49M
Net Income after Tax
FY2025Q2
YoY :
+29.41%
-0.88
EPS - Diluted
FY2025Q2
YoY :
+86.49%
-63.14M
Free Cash Flow
FY2025Q2
N/A
Gross Profit Margin - %
FY2025Q2
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q2
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
85.8K
Volume
2
0-12
Months
1.3M
Volume
5
Bought
0-3
0
0.0
Volume
Months
3-6
2
500.0K
Volume
Months
6-9
2
1.7M
Volume
Months
0-12
3
1.1M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
IDYA News & Events
Events Timeline
2025-10-20 (ET)
2025-10-20
06:39:12
Ideaya Biosciences unveils clinical findings from the OptimUM-09 trial
2025-10-20
06:05:17
Ideaya Biosciences announces overall survival results from darovasertib study
2025-09-08 (ET)
2025-09-08
08:09:47
Ideaya Biosciences to Showcase Preliminary Findings from Phase 1/2 Trial of IDE397
Sign Up For More Events
Sign Up For More Events
News
5.0
10-31PRnewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1.0
10-27PRnewswireIDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events
6.0
10-22NASDAQ.COMGoldman Sachs Upholds Neutral Rating for IDEAYA Biosciences (IDYA)
Sign Up For More News
People Also Watch
CIFR
Cipher Mining Inc
22.760
USD
+22.04%
WGS
GeneDx Holdings Corp
138.300
USD
+1.02%
ROCK
Gibraltar Industries Inc
61.480
USD
-1.46%
KMT
Kennametal Inc
22.180
USD
+1.05%
ALGT
Allegiant Travel Co
61.930
USD
-0.40%
INSW
International Seaways Inc
50.420
USD
-1.58%
PSEC
Prospect Capital Corp
2.610
USD
-1.88%
VYX
NCR Voyix Corp
11.340
USD
-0.61%
EVCM
EverCommerce Inc
11.420
USD
-1.47%
MQ
Marqeta Inc
4.495
USD
-0.77%
FAQ
What is IDEAYA Biosciences Inc (IDYA) stock price today?
The current price of IDYA is 31.36 USD — it has decreased -1.57 % in the last trading day.
What is IDEAYA Biosciences Inc (IDYA)'s business?
What is the price predicton of IDYA Stock?
What is IDEAYA Biosciences Inc (IDYA)'s revenue for the last quarter?
What is IDEAYA Biosciences Inc (IDYA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for IDEAYA Biosciences Inc (IDYA)'s fundamentals?
How many employees does IDEAYA Biosciences Inc (IDYA). have?